Drug profile · INN
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)
INCELLIPAN
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) (INCELLIPAN) is an FDA-listed pharmaceutical active ingredient.
Drug details — pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) (INCELLIPAN) is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)?
pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) (INCELLIPAN) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)?
INCELLIPAN is a marketed brand name for pandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures). Check FDA Drugs@FDA for the current US label holder and prescribing information.